Tern Plc Konektio £2.5 million equity fundraise

IoT

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that its portfolio company, InVMA Limited, which trades as Konektio has agreed a £2.5 million equity fundraise, to be completed in two tranches. The first tranche of £1.2 million has completed and the second tranche of £1.3 million is due for completion in Q4 2023.

Tern has invested £100,000 in the Konektio First Tranche, with the remainder provided by Konektio’s other institutional shareholders, being Mercia and Foresight.  Prior to the Konektio First Tranche, Tern had a shareholding of 39.9% in Konektio with an unaudited book valuation of £1.0 million.  Post the Konektio First Tranche, Tern’s shareholding in Konektio has reduced to 28% (before any dilution on exercise of any Konektio employee share options) and Tern’s shareholding now has an unaudited book valuation, at the Konektio First Tranche price, of £0.9 million.  

Including its participation in the Konektio First Tranche, Tern has, to date, invested approximately £2.3 million in Konektio.  The pre-new money valuation for the Konektio First Tranche is approximately equivalent to the pre-money valuation for the previous Konektio fundraise announced on 25 April 2023, with Konektio having increased its employee share option pool.

Tern Plc has committed to invest a minimum of £0.28 million in the Konektio Second Tranche, with an option, at its sole discretion, to increase its investment amount up to £0.4 million.  The price of the Konektio Second Tranche will be determined as at 30 September 2023 and will be based on the annualised revenues of Konektio at that time, capped at a pre money valuation of £6.0 million.  Should Tern not fulfil its commitment to invest a minimum of £0.28 million in the Konektio Second Tranche, 75% of Tern’s holding in Konektio will be transferred to a valueless class of Konektio deferred shares.

About Konektio

Konektio provides an Industrial IoT Software as a Service platform to Original Equipment Manufacturers and aftermarket customers, as well as the connected product market. The software enables remote asset monitoring and management to drive productivity improvements. Konektio’s primary product, AssetMinder, is machine agnostic and allows manufacturers to diagnose issues and proactively prescribe services plans, ultimately reducing downtime and improving operational efficiency.  According to the latest filed financial statements for Konektio, for the 12 month period ended 31 December 2021, the business recorded an increase in retained unaudited losses of £0.4 million and at that date had unaudited net assets of approximately £1.8 million.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

Search